Loading
Dermatology and Skin Diseases · Journal article
Journal of the European Academy of Dermatology and Venereology · August 10, 2026
A consensus or society position rather than new primary data.
This is a multidisciplinary expert consensus statement synthesizing evidence from RCTs and real-world studies on malignancy risk associated with biologic and oral targeted therapies for psoriasis and atopic dermatitis. The authors report that overall malignancy risk is low for most agents, but acknowledge significant evidence gaps, particularly for patients with active or prior malignancy—populations typically excluded from pivotal trials.
Narrative synthesis and expert consensus statement. Evidence reviewed for patients with psoriasis or atopic dermatitis, with specific focus on those with current malignancy, prior malignancy, or increased cancer risk—populations typically excluded from RCTs. Intervention: Biologic and oral targeted therapies (specific agents not enumerated in abstract).
Overall malignancy risk associated with most biologic and oral targeted therapies is low, although differences between therapeutic classes may exist Real-world data remain limited for several therapeutic classes and in patients with active or previous malignancy
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians facing treatment decisions in cancer-vulnerable populations should use these consensus recommendations to balance disease control against malignancy risk; however, the admission of limited real-world data in key subgroups means individual risk assessment remains essential and gaps in evidence should inform shared decision-making.
Expert consensus recommendations synthesizing RCT and real-world evidence on malignancy risk with biologic and oral targeted therapies in psoriasis and atopic dermatitis, addressing a clinically important gap in populations excluded from trials.
As stated by the source record.
Clinicians facing treatment decisions in cancer-vulnerable populations should use these consensus recommendations to balance disease control against malignancy risk; however, the admission of limited real-world data in key subgroups means individual risk assessment remains essential and gaps in evidence should inform shared decision-making.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
What is missing. This record has no reported figures. That is a gap in the analysis, not a judgement about the study.
BACKGROUND: The expanding use of biologic and oral targeted therapies has transformed the management of psoriasis and atopic dermatitis. These agents are increasingly prescribed to patients with current malignancy, a history of malignancy or an increased cancer risk, populations typically excluded from clinical trials. In the absence of robust long-term safety data, clinicians often rely on real-world evidence to inform treatment decisions. OBJECTIVES: To review the evidence regarding malignancy risk associated with biologic and oral targeted therapies used in psoriasis and atopic dermatitis and to provide expert consensus recommendations for patients with current malignancy, previous malignancy or increased risk of malignancy. METHODS: We describe the physiological roles of key immune pathways targeted in psoriasis and atopic dermatitis, as well as in cancer immunosurveillance, tumour progression and immune escape. We then summarize evidence from randomized controlled trials regarding the risk of de novo malignancy, followed by a synthesis of real-world data addressing cancer recurrence and progression in patients treated with biologic and oral targeted therapies. RESULTS: Available evidence suggests that the overall malignancy risk associated with most biologic and oral targeted therapies used in psoriasis and atopic dermatitis is low, although differences between therapeutic classes may exist. Real-world data remain limited for several therapeutic classes and in patients with active or previous malignancy. CONCLUSIONS: Based on the available evidence, we present consensus-based recommendations developed by a multidisciplinary expert panel convened by the Skin Inflammation & Psoriasis International Network-Fondation René Touraine (SPIN-FRT). These recommendations aim to support treatment decisions by balancing disease control with potential cancer-related risks while highlighting key evidence gaps.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.